Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Charles Obrien

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentInternal Med, College of Medicine
DivisionInternal Med Endo
Address834 Cancer Institute
4104 Outpatient Circle
Mail Slot # 587
Little Rock AR 72205
Phone501-214-2180
vCardDownload vCard
    Other Positions
    TitleProfessor
    InstitutionUniversity of Arkansas for Medical Sciences
    DepartmentOrthopaedics, College of Medicine


    Collapse Research 
    Collapse research activities and funding
    2P20GM125503     (OBRIEN, CHARLES A)Apr 1, 2023 - Jun 30, 2028
    NIH/Nat. Inst. of General Medical Sciences
    Center for Musculoskeletal Disease Research (CMDR)
    Role: Principal Investigator
    2P20GM125503-06     (OBRIEN, CHARLES A)Apr 1, 2023 - Jan 31, 2028
    NIH/Nat. Inst. of General Medical Sciences
    Center for Musculoskeletal Disease Research (CMDR)
    Role: Principal Investigator
    P20 GM125503-06     (Obrien, Charles)Apr 1, 2023 - Jan 31, 2028
    NIH/Nat. Inst. of General Medical Sciences
    Center for Musculoskeletal Disease Research (COBRE)
    Role: Principal Investigator
    P20GM125503     (OBRIEN, CHARLES A)Apr 1, 2023 - Jan 31, 2028
    NIH/Nat. Inst. of General Medical Sciences
    Center for Musculoskeletal Disease Research (CMDR)
    Role: Principal Investigator
    2R01AR049794     (OBRIEN, CHARLES A)Apr 1, 2022 - Mar 31, 2027
    NIH/Nat. Inst. of Arthritis & Musculoskeletal & Skin Diseases
    Osteocyte Control of Bone Remodeling
    Role: Principal Investigator
    2R01AR049794-16A1     (OBRIEN, CHARLES A)Apr 1, 2022 - Mar 31, 2027
    NIH/Nat. Inst. of Arthritis & Musculoskeletal & Skin Diseases
    Osteocyte Control of Bone Remodeling
    Role: Principal Investigator
    R01 AR49794-16     (Obrien, Charles)Apr 1, 2022 - Mar 31, 2027
    NIH/Nat. Inst. of Arthritis & Musculoskeletal & Skin Diseases
    Osteocyte Control of Bone Remodeling
    Role Description: The goal of this project is to identify the mechanisms responsible for the rapid bone loss that occurs after cessation of anti-RANKL therapy.
    Role: Principal Investigator
    R01AR049794     (OBRIEN, CHARLES A)Apr 1, 2022 - Mar 31, 2027
    NIH/Nat. Inst. of Arthritis & Musculoskeletal & Skin Diseases
    Osteocyte Control of Bone Remodeling
    Role: Principal Investigator
    1R01AG068449     (OBRIEN, CHARLES A)Apr 1, 2021 - Dec 31, 2025
    NIH/Nat. Inst. on Aging
    Different consequences of cellular aging in cortical versus cancellous bone
    Role: Principal Investigator
    1R01AG068449-01A1     (OBRIEN, CHARLES A)Apr 1, 2021 - Dec 31, 2025
    NIH/Nat. Inst. on Aging
    Different consequences of cellular aging in cortical versus cancellous bone
    Role: Principal Investigator
    R01AG068449     (OBRIEN, CHARLES A)Apr 1, 2021 - Dec 31, 2025
    NIH/Nat. Inst. on Aging
    Different consequences of cellular aging in cortical versus cancellous bone
    Role: Co-Principal Investigator
    S10 OD026736     (MACKINTOSH, SAMUEL)Aug 1, 2019 - Jul 31, 2020
    NIH/Office of the Director
    Q Exactive HF-X Hybrid Quadrupole Orbitrap Mass Spectrometer
    Role: Co-Investigator
    S10OD026736     (MACKINTOSH, SAMUEL G.)Aug 1, 2019 - Jul 31, 2020
    NIH
    Q Exactive HF-X Hybrid Quadrupole Orbitrap Mass Spectrometer
    Role: Co-Investigator
    R21AR069253     (PORTER, RYAN MICHAEL)Feb 7, 2016 - Jan 31, 2019
    NIH
    A Transgenic Rat for Noninvasive Assessment of Chondrogenic Activity in vivo
    Role: Principal Investigator
    P20GM109005     (BOERMA, MARJAN)Jun 24, 2015 - May 31, 2025
    NIH
    Center for Studies of Host Response to Cancer Therapy
    Role: Co-Investigator
         (O'BRIEN, CHARLES A)Oct 1, 2013 - Sep 30, 2017
    Veterans Administration
    RANKL and Lymphocyte Mediated Bone Loss
    Role: Principal Investigator
    I01BX000294     (O'BRIEN, CHARLES A)Apr 1, 2009 - Dec 31, 2022
    NIH
    Molecular mechanisms of glucocorticoid-induced bone loss
    Role: Principal Investigator
    R01AR056679     (SCHULLER DE ALMEIDA, MARIA)Dec 1, 2008 - Jan 31, 2022
    NIH/Nat. Inst. of Arthritis & Musculoskeletal & Skin Diseases
    Role of FoxOs in Skeletal Homeostasis- Resubmission - Continuation-Continuation - Continuation - Continuation
    Role: Co-Investigator
    R01AR045241     (OBRIEN, CHARLES A)Sep 1, 1998 - Aug 31, 2004
    NIH/Nat. Inst. of Arthritis & Musculoskeletal & Skin Diseases
    In Vivo Regulation of IL6 and IL6R Gene Expression
    Role: Principal Investigator
    R29AR045241     (O'BRIEN, CHARLES A)Sep 1, 1998 - Aug 31, 2003
    NIH
    IN VIVO REGULATION OF IL6 AND IL6R GENE EXPRESSION
    Role: Principal Investigator
    P01AG013918     (MANOLAGAS, STAVROS C.)Aug 27, 1996 - Apr 30, 2018
    NIH
    Molecular and Cellular Mechanisms of Osteoporosis
    Role: Co-Investigator

    Collapse Bibliographic 
    Collapse additional bibliographic sources
    The links below are provided by the researcher to provide access to external online bibliographies that they keep independently from the Profiles System.
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. MacLeod RS, Meyer MB, Xiong J, Cawley KM, Liu Y, Onal M, Benkusky NA, Thostenson JD, Pike JW, O'Brien CA. Deletion of a putative promoter-proximal Tnfsf11 regulatory region in mice does not alter bone mass or Tnfsf11 expression in vivo. PLoS One. 2021; 16(5):e0250974. PMID: 33970941.
      View in: PubMed
    2. O'Brien CA, Nakashima T, Takayanagi H. Osteocyte control of osteoclastogenesis. Bone. 2013; 54(2):258-63.
    3. Jilka RL, O'Brien CA, Roberson PK, Bonewald LF, Weinstein RS, Manolagas SC. Dysapoptosis of osteoblasts and osteocytes increases cancellous bone formation but exaggerates bone porosity with age. J Bone Mineral Res. 2013.
    4. Almeida M, Iyer S, Martin-Millan M, Bartell SM, Han L, Ambrogini E, Onal M, Xiong J, Weinstein RS, Jilka RL, O'Brien CA, Manolagas SC. Estrogen receptor-alpha signaling in osteoblast progenitors stimulates cortical bone accrual. J Clin Invest. 2013; 123(1):394 - 404.
    5. Onal M, Xiong J, Chen X, Thostenson JD, Almeida M, Manolagas SC, O'Brien CA. Receptor activator of nuclear factor kappaB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J Biol Chem. 2012; 287(35):29851 - 29860.
    6. Xiong J, O'Brien CA. Osteocyte RANKL: new insights into the control of bone remodeling. J Bone Miner Res. 2012; 27(3):499 - 505.
    7. O'Brien CA. Control of RANKL gene expression. Bone. 2010; 46(4):911 - 919.
    8. O'Brien,CA. Control of RANKL gene expression. Bone. 2010; 46:911-919.
    9. O'Brien CA, Kern B, Gubrij I, Karsenty G, Manolagas SC. Cbfa1 does not regulate RANKL gene activity in stromal/osteoblastic cells. Bone. 2002 Mar; 30(3):453-62. PMID: 11882458.
      View in: PubMed
    10. Shi H, O'Brien CA, Van Horn DJ, Wolin SL. A misfolded form of 5S rRNA is complexed with the Ro and La autoantigens. RNA. 1996; 2(8):769 - 784.
    11. Manolagas SC, Jilka RL, Bellido T, O'Brien CA, Parfitt, AM. Principles of bone biology. Interleukin-6-type cytokines and their receptors. 1996.
    12. Ge Q, Nilasena DS, O'Brien CA, Frank MB, Targoff IN. Molecular analysis of a major antigenic region of the 240-kD protein of Mi-2 autoantigen. J Clin Invest. 1995; 96(4):1730 - 1737.
    13. Van Horn DJ, Eisenberg D, O'Brien CA, Wolin SL. Caenorhabditis elegans embryos contain only one major species of Ro RNP. RNA. 1995; 1(3):293 - 303.
    14. Farris AD, O'Brien CA, Harley JB. Y3 is the most conserved small RNA component of Ro ribonucleoprotein complexes in vertebrate species. Gene. 1995; 154(2):193 - 198.
    15. O'Brien CA, Wolin SL. A possible role for the 60-kD Ro autoantigen in a discard pathway for defective 5S rRNA precursors. Genes Dev. 1994; 8(23):2891 - 2903.
    16. O'Brien CA, Margelot K, Wolin SL. Xenopus Ro ribonucleoproteins: members of an evolutionarily conserved class of cytoplasmic ribonucleoproteins. Proc Natl Acad Sci U S A. 1993; 90(15):7250 - 7254.
    17. Ge Q, Frank MB, O'Brien C, Targoff IN. Cloning of a complementary DNA coding for the 100-kD antigenic protein of the PM-Scl autoantigen. J Clin Invest. 1992; 90(2):559 - 570.
    18. O'Brien CA, Harley JB. Association of hY4 pseudogenes with Alu repeats and abundance of hY RNA-like sequences in the human genome. Gene. 1992; 116(2):285 - 289.
    19. O'Brien CA, Harley JB. A subset of hY RNAs is associated with erythrocyte Ro ribonucleoproteins. EMBO J. 1990; 9(11):3683 - 3689.
    20. James JA, Dickey WD, Fujisaku A, O'Brien CA, Deutscher SL, Keene JD, Harley JB. Antigenicity of a recombinant Ro (SS-A) fusion protein. Arthritis Rheum. 1990; 33(1):102 - 106.
    21. Mamula MJ, O'Brien CA, Harley JB, Hardin JA. The Ro ribonucleoprotein particle: induction of autoantibodies and the detection of Ro RNAs among species. Clin Immunol Immunopathol. 1989; 52(3):435 - 446.
    22. Targoff IN, Arnett FC, Berman L, O'Brien C, Reichlin M. Anti-KJ: a new antibody associated with the syndrome of polymyositis and interstitial lung disease. J Clin Invest. 1989; 84(1):162 - 172.
    23. Rader MD, O'Brien C, Liu YS, Harley JB, Reichlin M. Heterogeneity of the Ro/SSA antigen. Different molecular forms in lymphocytes and red blood cells. J Clin Invest. 1989; 83(4):1293 - 1298.
    24. Jilka RL, Bellido T, Almeida M, Plotkin LI, O'Brien CA, Weinstein RS, Manolagas SC. Principles of bone biology. Apoptosis of Bone Cells.
    Obrien's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (31) concept(s)
    _
    Co-Authors Expand Description
    See all (2) people
    _
    Similar People Expand Description
    See all (29) people
    _
    Same Department Expand Description
    Search Department